Financials in USD. Standardized financial statements.
A compact view of how Verve Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue? | $32.33M | $11.76M | $1.94M | $0 | $0 | $0 |
| Revenue Growth? | +175.0% | +505.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $3.38M | $1.33M | $106,000 |
| Gross Profit? | $32.33M | $11.76M | $1.94M | -$3.38M | -$1.33M | -$106,000 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $260.99M | $234.88M | $167.63M | $87.07M | $40.63M | $13.64M |
| Operating Income? | -$228.66M | -$223.12M | -$165.69M | -$87.07M | -$40.63M | -$13.64M |
| EBITDA? | -$221.91M | -$217.67M | -$162.88M | -$85.53M | -$39.30M | -$13.54M |
| Income Before Tax | -$198.36M | -$199.79M | -$157.33M | -$120.31M | -$45.70M | -$19.30M |
| Income Tax Expense | $349,000 | $275,000 | $53,000 | $0 | $0 | $0 |
| Net Income? | -$198.71M | -$200.07M | -$157.39M | -$118.64M | -$45.54M | -$19.02M |
| EPS? | $-2.36 | $-3.12 | $-2.91 | $-2.45 | $-0.94 | $-0.65 |
| Diluted EPS? | $-2.35 | $-3.12 | $-2.91 | $-2.45 | $-0.94 | $-0.65 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality